ProjectRD.06.SPR.202685 – A study to assess the efficacy and safety of nemolizumab (CD14152) insubjects with prurigo…
Basic data
Acronym:
RD.06.SPR.202685
Title:
A study to assess the efficacy and safety of nemolizumab (CD14152) insubjects with prurigo nodularis (PN)
Duration:
04/05/2020 to 30/09/2022
Abstract / short description:
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the
Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
Keywords:
Prurigo nodularis
Involved staff
Managers
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Contact persons
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
CRC-TR 156 - The Skin as a Sensor and Effector Organ Orchestrating Local and Systemic Immune Responses
Collaborative research centers and transregios
Collaborative research centers and transregios
Cluster of Excellence: Image-Guided and Functionally Instructed Tumor Therapies (iFIT)
Centers or interfaculty scientific institutions
Centers or interfaculty scientific institutions
Local organizational units
Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine
Faculty of Medicine
Funders
La Tour-de-Peilz, Switzerland